ArticleCancers2026
LSC-like Phenotypes Aid in the Prognosis of Adult and Elderly Acute Myeloid Leukemia Patients at a Resource-Limited Health Center.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND/
objectivesRelapse is the greatest obstacle in treating acute myeloid leukemia (AML), occurring in 40-50% of younger patients and most elderly patients. Current immunophenotyping panels for diagnosis and detection of measurable residual disease (MRD) primarily focus on detecting blasts, thereby overlooking AML heterogeneity, which could provide valuable prognostic insights. In this context, we propose repositioning EuroFlow panels within a new set of analyses to assess leukemia stem-like phenotypes for AML prognostic monitoring.
methodsWe performed a retrospective study with AML patients at the Hospital de Clínicas de Porto Alegre between 2015 and 2023.
resultsOur findings highlight the relevance of leukemia stem cell-like phenotypes, particularly the CD123+, CD34+CD123+, and CD34+CD38- subpopulations, for complementary prognostication of adult and elderly patients. A higher percentage of CD123+ cells was a risk factor for both RFS (
conclusionsRepositioning immunophenotypic analyses may offer a cost-effective alternative for refined prognostication, particularly in healthcare centers that already have flow cytometry-based AML diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.